ISPOR Forums
Monday, May 18, 2015
6:15 PM - 7:15 PM
ISPOR FORUMS - SESSION I

6:15 PM - 7:15 PM
Room: Grand Ballroom, Salon H (Level 5)
F1: MEASUREMENT OF HEALTH STATE UTILITY VALUES FOR ECONOMIC MODELS IN CLINICAL STUDIES – FINDINGS OF THE GOOD PRACTICES TASK FORCE
Moderator:

Sorrel Wolowacz, PhD, Head, European Health Economics, RTI Health Solutions, Manchester, UK

Speakers:

Andrew Briggs, DPhil, MSc, William R. Lindsay Professor of Health Economics, Health Economics & Health Technology Assessment, Institute of Health & Wellbeing, University of Glasgow, Glasgow, UK

Lynda Doward, MRes, European Head, Patient-Reported Outcomes, RTI Health Solutions, Manchester, UK

Andrew Lloyd, PhD, Scientific Advisor, Patient Reported Outcomes, ICON plc., Oxford, UK

DESCRIPTION:

The quality of health state utility values (HSUVs) used in health economic models is critical to the quality of cost-utility analyses, and to the health technology assessment decision-making processes which determine whether new medicines are made available to patients in many countries.  It has become increasingly common for health utility data to be collected alongside clinical trials; however, such data often have provided sub-optimal HSUV estimates for economic models for a variety of reasons.  This forum will present the work of the Task Force which is developing Good Practices for measuring HSUVs for economic models in clinical studies.  The audience will be invited to comment and provide feedback on the findings of the Task Force and the preliminary recommendations of the Task Force Report. Presented by the ISPOR Measurement of Health State Utility Values for Economic Models in Clinical Studies — Good Practices Task Force


6:15 PM - 7:15 PM
Room: Grand Ballroom, Salon C, D, E (Level 5)
F2: CLINICAL OUTCOME ASSESSMENTS (COAS): A CONCEPTUAL FOUNDATION AND DEVELOPING AND EVALUATING CLINICIAN-REPORTED OUTCOME (CLINRO) INSTRUMENTS TO ASSESS TREATMENT BENEFIT: EMERGING GOOD PRACTICES
Moderator:

John H. Powers, MD, FACP, FIDSA, Associate Clinical Professor of Medicine, George Washington University School of Medicine, Washington, DC, USA

Speakers:

Laurie B. Burke, RPh, MPH, Founder, Lora Group, LLC, Royal Oak, MD, USA and Former Director, Study Endpoints and Labeling Development, ONDIO, CDER, U.S. Food & Drug Administration, Silver Spring, MD, USA

Donald Patrick, PhD, MSPH, Professor, Department of Health Services & Director, Seattle Quality of Life Group & Biobehavioral Cancer Training Program, University of Washington, Seattle, WA, USA

Stefan Cano, PhD, CPsychol, AFBPsS, Co-Founder and Chief Science Officer, Modus Outcomes, Stotfold, UK

Patrick Marquis, MD, MBA, President, Twolegs Consulting, Newton, MA, USA

DESCRIPTION:

There is an urgent need for a standardized conceptual foundation for clinical outcome assessments (COAs) – ClinRO, ObsRO, PRO, or PerfO measures.  The differences in each type of instrument dictate different approaches for development and evaluation.  The Task Force undertook guidelines for ClinRO instruments.  Task Force members will open discussion by defining what should be considered a ClinRO measure and providing a framework to describe these types of measures.  They will present US (FDA) and European Medicines Agency (EMA) regulatory perspectives as well as their final recommendations on evaluation of ClinRO instruments for use to document treatment benefit.  Identification of the treatment benefit and endpoint based on a ClinRO score, the concept of interest that is measured and context of use, evaluation of the instrument’s measurement properties will be included.  Guidelines for interpretation and implementation in clinical trials conclude the discussion.  The findings of these two Task Force reports will be very beneficial to those involved in evaluating treatment benefit using any type of COA. Presented by the ISPOR Clinical Outcomes Assessment – Emerging Good Practices Task Force


6:15 PM - 7:15 PM
Room: Grand Ballroom, Salon A, B, F (Level 5)
F3: PATIENT ENGAGEMENT IN HEALTH ECONOMIC AND OUTCOMES RESEARCH: CURRENT AND FUTURE ISPOR INITIATIVES
Moderator:

Todd Berner, MD, XX, XX, XX, Northbook, IL, USA

Speakers:

Amie Scott, MPH, Business Health Research Analyst, SEAS Capital Partners, LLC, Plymouth, MI, USA

Don Husereau, BScPharm, MSc, Senior Associate, Institute of Health Economics & Adjunct Professor, Epidemiology and Community Medicine, University of Ottawa, Ottawa, ON, Canada

Emil Chiauzzi, PhD, Research Director, PatientsLikeMe, Cambridge, MA, USA

Rob Camp, Communications Manager, EUPATI, Barcelona, Spain

DESCRIPTION:

ISPOR has continued to focus on the role and involvement of patients in health outcomes research and decision making. This forum will explore issues identified by patients in current ISPOR patient initiatives, including patient representative roundtables and special interest groups. During this forum, directions for further involvement and work of patients will be presented and discussion of next steps explored with audience members. Presented by the ISPOR Patient-Centered Special Interest Group, ISPOR European Patient Representative Roundtable, and ISPOR North American Patient Representative Roundtable


6:15 PM - 7:15 PM
Room: Grand Ballroom, Salon K-L (Level 5)
F4: FROM COST-EFFECTIVENESS TO EQUITY: CHALLENGES FACING HEALTH CARE SYSTEMS IN LATIN AMERICA
Moderator:

Hector Castro, MD, MS, PhD, Chief Executive Officer, Health Technology Assessment Institute of Colombia (IETS), Bogota, Colombia

Speakers:

Marcelo Fonseca, MD, MSc, Professor, Assistant Physician, Federal University of São Paulo, São Paulo, Brazil

Rosa Maria Galindo Suarez, MHA, Deputy General Director of Prioritization, General Health Council, Mexico City, Mexico

Manuel Antonio Espinoza, MD, MSc, PhD, Chair-elect, ISPOR Latin America Consortium Executive Committee, Professor of Health Economics and Chief Unit of Health Technology Assessment, Faculty of Medicine, Santiago, Chile

Diego Rosselli, MD, MEd, MSc, Associate professor, Clinical Epidemiology and Biostatistics Department, Pontificia Universidad Javeriana, Bogota, Colombia

DESCRIPTION:

The right to health is part of the constitutional rights of all states in Latin America and frequently access to health care interventions is being determined by judicial decision, as individuals make claim to their right to health, without an allowance for careful consideration of the potential budget impact of these health technologies. This has serious implications for the role of ‘cost-effectiveness’ in the region’s health care systems. This forum will address some of the issues surrounding this apparent dichotomy, and will reference a recent presentation from the ISPOR Latin America Consortium and SaluDerecho (The World Bank). Presenters will frame discussion in the context of the theme for the ISPOR 5th Latin America Conference: Access to Health Care in Latin America: Making Better Decisions for Greater Equity, taking place 6-8 September, 2015 in Santiago, Chile. Presented by the ISPOR Latin America Consortium


6:15 PM - 7:15 PM
Room: Grand Ballroom, Salon G (Level 5)
F5: INTEGRATING BIG DATA INTO REAL WORLD PRACTICE
Moderator:

Zeba M. Khan, RPh, PhD, Vice President, Celgene Corporation, Summit, NJ, USA

Speakers:

William H. Crown, PhD, Chief Scientific Officer, Optum Labs, Cambridge, MA, USA

Marc Berger, MD, Vice President, Real World Data and Analytic, Pfizer, Inc., New York, NY, USA

DESCRIPTION:

This forum will focus on how big data is currently used and predictions for the future. Speakers will also identify ways students can develop skill sets related to the integration of big data into real world practice. Presented by the ISPOR Student Council


6:15 PM - 7:15 PM
Room: Grand Ballroom, Salon I (Level 5)
F6: SYNCING INFORMATION CHAINS WITH HEALTH SYSTEMS DEVELOPMENT FOR BETTER OUTCOMES
Moderator:

Gabriela Tannus, MBA, MSc, Owner & Health Economics Director, Axia.Bio Consulting, Sao Paolo, Brazil

Speakers:

Vitaly V. Omelianovskiy, MD, PhD, Director, Centre of HTA, Moscow, Russia

Jitendar Sharma, PhD, Head, Division of Healthcare Technology, National Health Systems Resource Center, Ministry of Health & Family Welfare, New Delhi, India

Kun Zhao, MD, PhD, Professor & Director, Division of Health Technology Assessment, China National Health Development, Research Center, National Health and Family Planning Commission (NHFPC), Beijing, China

Nikash Bagirathi, BSc, Bmed (Hons), Managed Healthcare Manager, Medtronic, Johannesburg, South Africa

DESCRIPTION:

Health Systems of the BRICS countries (Brazil, Russia, India, China and South Africa) are undergoing dramatic change as information revolutions in patient data and informatics take hold. The “Information Chain,” which includes data collection, data management, and data utilization will have a large impact on health outcomes. For collection, how are countries effectively contributing to the evidence base through timely and accurate research? For management, how are countries using new technology and analytics to store, share, and interpret the data? And for utilization, how are countries effectively translating the data into useful information for decision makers to improve health outcomes? Finally, how are countries building up the necessary capacity and infrastructure to ensure that the above “Information Chain” remains strong? Presented by the ISPOR BRICS


6:15 PM - 7:15 PM
Room: Grand Ballroom, Salon J (Level 5)
F7: BUDGET IMPACT ANALYSIS OF EPIDEMIC DISEASES ACROSS AFRICA
Moderator:

Anthony Waka Udezi, PhD, President, ISPOR Nigeria Chapter, Associate Professor & Assistant Dean, Department of Clinical Pharmacy, University of Benin, Benin City, Nigeria

Speakers:

Peter Agyei-Baffour, PhD, President, ISPOR Ghana Chapter and Lecturer & Researcher, Department of Community Health, School of Medical Sciences, Kwame Nkrumah University of Sciences and Technology (KNUST), Kumasi, Ghana

Paul La Cock, MPharm, Consultant, inScisive, Cape Town, South Africa

Abdalla Aly, BPharm, PhD, Associate Scientist, Health Economics and Outcomes, Pharmerit International, Bethesda, MD, USA

DESCRIPTION:

Africa has struggled with many health issues over the past decades. This forum will focus on the impact of local epidemics on the allocation of health care budgets in Africa with an approach from a public perspective. Speakers will examine the implications of different epidemics on medical, economical, and societal aspects of life in the Africa region. Examples from various countries and most relevant diseases will be discussed from a budget impact point of view. Presented by the ISPOR Africa Network

Tuesday, May 19, 2015
6:15 PM - 7:15 PM
ISPOR FORUMS - SESSION II

6:15 PM - 7:15 PM
Room: Grand Ballroom, Salon C, D, E (Level 5)
F8: INCORPORATING EQUITY INTO HTA: METHODS, TOOLS AND APPLICATIONS IN LATIN AMERICA
Moderator:

Manuel Espinoza, MD, MSc, PhD, Assistant Professor, Department of Public Health & Coordinator, Unit of Health Technology Assessment, Center for Clinical Investigation, Catholic University of Chile, Santiago, Chile

Speakers:

Praveen Thokala, MASc, PhD, Research Fellow, University of Sheffield, Sheffield, UK

Clarice Petramale, MD, Director, Department of Management and Health Technology Incorporation, Secretariat of Science, Technology and Strategic Input, Minister of Health, Brasilia, Brazil

Alexandre Lemgruber, Regional Advisor in Health Technologies, Pan American Health Organization (Invited), Washington, DC, USA

Mike Paulden, MA, MSc, Senior Research Associate, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada

DESCRIPTION:

The ISPOR 2020 Vision (http://www.ispor.org/ISPOR-Good-Practices-for-Development.pdf) defines generating, synthesizing, and utilizing evidence on equity evaluation methods within the context of health outcomes as a priority area of action. This forum seeks to first review three methods and tools for integrating equity into health technology assessment: the Equity checklist: a Framework for Health Technology Assessment; Equity-Oriented Toolkit for needs-based health technology assessment, and the use of relative weights and opportunity cost. Later, it will discuss Brazil's experience with testing equity integration methods at CONITEC. Presented by the ISPOR Latin America Consortium


6:15 PM - 7:15 PM
Room: Grand Ballroom, Salon G (Level 5)
F9: MANAGING COSTS AND IMPROVING QUALITY OF HEALTH CARE IN ASEAN
Moderator:

Surachat Ngorsuraches, PhD, Associate Professor, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Songkla, Thailand

Speakers:

Thuy Nguyen, PhD, Lecturer, Ho Chi Minh City University of Medicine and Pharmacy, Ho Chi Minh City, Vietnam

Soraya Azmi, MD, MPH, Managing Director, Azmi Burhani Consulting, Petaling Jaya, Malaysia

Bayu Teja Muliawan, Director, Pharmaceutical Service, Ministry of Health of the Republic of Indonesia, Jakarta, Indonesia

Miny Lu, MD, PhD, Director, Healthcare Economics, Policy and Reimbursement, Medtronic, Singapore, Singapore

DESCRIPTION:

Health care expenditures throughout the ASEAN (Association of Southeast Asian Nations) are growing as incomes rise and citizens demand better provision and quality of care. According to the World Health Organization (WHO), health expenditure in ASEAN nations increased by 150% between 1998 and 2010, reaching nearly $70 billion. ASEAN countries are finding themselves searching for new ways to manage rising costs while still providing greater access to care, even as citizens demand more from their governments. New regional health care trends including growth of private hospitals, public-private partnerships (PPP), medical tourism, and universal coverage stress the need for further collaboration and parity between private and public sectors, as well as region-wide partnerships to tackle new challenges on the horizon. Presented by the ISPOR Asia Consortium


6:15 PM - 7:15 PM
Room: Grand Ballroom, Salon A, B, F (Level 5)
F10: THE ISSUES AND CHALLENGES FACING THE LIFE SCIENCE INDUSTRY TODAY
Moderator:

John O’Donnell, PhD, Vice President, Worldwide Health Economics & Outcomes Research, Bristol-Myers Squibb Co., Princeton, NJ, USA

Speakers:

Donald Yin, PhD, Associate Vice President, Merck & Co. Inc., Lebanon, NJ, USA

James F. Murray, PhD, Research Fellow, Global Health Outcomes - COE, Eli Lilly and Company, Carmel, IN, USA

DESCRIPTION:

In a recent member survey, the ISPOR Institutional Council polled members from the Life Science Industry on critical issues and significant challenges to the life sciences community such as development and research productivity, industry reputation, pricing pressures, and ensuring the credibility of today’s science and evidence.  The ISPOR Institutional Council has existed for more than 15 years and is dedicated to raising awareness of health economics and outcomes research and promoting good research practices within the ISPOR membership and global community.  The Institutional Council also serves as a resource and discussion forum on new issues that impact all stakeholders.  Join us in exploring critical changes and opportunities facing industry today and discussing how the ISPOR Institutional Council can effectively respond to our complex and evolving environment. Presented by the ISPOR Institutional Council


6:15 PM - 7:15 PM
Room: Grand Ballroom, Salon K-L (Level 5)
F11: MANAGED ENTRY AGREEMENTS (MEA) IN EGYPT, LEBANON, SAUDI ARABIA, AND UNITED ARAB EMIRATES
Moderator:

Abdulaziz H. Al-Saggabi, MSc, PharmD, President, ISPOR Saudi Arabia Chapter and Director, Drug Policy & Economics Center, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia

Speakers:

Mahmoud Elmahdawy, PharmD, President, ISPOR Egypt Chapter, Chair-Elect , ISPOR Africa Network and Administrations Manager, Hospital Pharmacy, Ministry of Health, Cairo, Egypt

Ola Ghaleb Al Ahdab, PhD, President, ISPOR United Arab Emirates Chapter and, Pharmaceutical Advisor & Project Manager, Registration and Drug Control Department, Ministry of Health, Abu Dhabi, United Arab Emirates

Soumana Nasser, PharmD, Clinical Associate Professor, Chair, Pharmacy Practice Department, School of Pharmacy, Lebanese American University, Byblos, Lebanon

DESCRIPTION:

Middle East is a diversified region with great variations across countries in terms of demographics, economy, GDP, and health conditions. This forum will discuss better utilization of Managed Entry Agreements (MEA) and their important role in increasing patients' access to innovative drugs. Speakers will shed more light on successful MEA models implemented in their respective countries and provide recommendations with examples from high and low middle-income countries in the region. Presented by the ISPOR Arabic Network


6:15 PM - 7:15 PM
Room: Grand Ballroom, Salon H (Level 5)
F12: FUNDING HEALTH TECHNOLOGY ASSESSMENT IN CENTRAL AND EASTERN EUROPEAN COUNTRIES: LOW PUBLIC BUDGET REFLECTS LOW PUBLIC PRIORITY?
Moderator:

Vladimir Zah, PhD candidate and Health Economics Consultant & Founder, ZRx Outcomes Research Inc., Belgrade, Serbia and Montenegro

Speakers:

Joanna Lis, PhD, President, ISPOR Poland Chapter, Adjunct Professor, Pharmacoeconomics Department, Medical University of Warsaw, and Director, Market Access, Sanofi, Warsaw, Poland

Vitaly Omelianovsky, MD, PhD, DSc, President, ISPOR Russia HTA Chapter, Professor & Director, Center for Health Technology Assessment of the Russian Presidential Academy of National Economy and Public Administration, Moscow, Russia

John Yfantopoulos, PhD, President, ISPOR Greece Chapter and Professor of Health Economics, School of Economics and Political Science, University of Athens, Athens, Greece

Zoltán Kaló, PhD, MD, MSc, Chair, ISPOR CEE Network Executive Committee, Professor of Health Economics, Department of Health Policy and Health Economics, Eötvös Loránd University (ELTE), Founder & CEO, Syreon Research Institute, Budapest, Hungary

DESCRIPTION:

In general, public budgets for health technology assessment (HTA) is more limited in CEE countries than in Western European countries. Participants will present examples of how HTA is funded in selected CEE countries and will discuss potential consequences of scarce HTA resources. As the opportunity cost of inappropriate reimbursement decisions is greater in countries with more limited health care resources, HTA implementation should be strengthened in CEE. Presented by the ISPOR CEE Network


6:15 PM - 7:15 PM
Room: Grand Ballroom, Salon I (Level 5)
F13: THE ROLE OF HTA IN THE QUEST TOWARDS UNIVERSAL COVERAGE IN MEXICO: A GOVERNMENT, ACADEMIC AND INDUSTRY PERSPECTIVE
Moderator:

César Alberto Cruz Santiago, MD, PhD, Advisor, Medical Director Area, PEMEX (Petróleos Mexicanos), Mexico City, Mexico

Speakers:

Gabriela Andrea Luna Ruíz, PhD, Professor, Economics Department, Universidad Iberoamericana, Ciudad de México, Mexico City, Mexico

Adolfo Hernández-Garduño, MD, MSc, PhD, Access Planning Senior Manager, Access Department, Janssen Cilag Mexico, Mexico City, Mexico

Jocelyn Ramírez Gámez, MSc, Pharmacoeconomics Manager, Government Sales, Eli Lilly, Mexico City, Mexico

DESCRIPTION:

Since 2002, Mexico has passed different health care reform legislation and programs designed to achieve nearly universal coverage. Ten years later, there are several analyses that recapitulate major achievements and objectives still to be met. This panel intends to discuss: What has been the impact of the many attempts made by Mexico to achieve universal coverage?; What is the role of HTA in the quest?; What should be the roles of the government, academia, Industry, and other stakeholders? Presented by the ISPOR Mexico Chapter

Contact ISPOR @ info@ispor.org | View Legal Disclaimer
© 2018 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.